Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.
Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: We evaluated the frequencies of Th17 cells in freshly isolated PBMCs and BMMCs from AML patients and compared them with those in PBMCs and BMMCs from healthy donors. After gating on CD3+CD8- T cells, intracellular production of IL-17A and IFN-γ were analyzed. The frequencies of Th17 cells were 3.59 ± 0.37% in AML PBMCs compared with 1.47 ± 0.14% in healthy donor PBMCs (P < 0.01) and 3.40 ± 0.21% in AML BMMCs compared with 1.51 ± 0.48% in healthy donor BMMCs (P < 0.01) (Fig. 1b). The frequencies of Th17 cells were significantly increased in PBMCs and BMMCs from AML patients compared with those in healthy donor PBMCs and BMMCs, whereas the frequencies of Th1 cells were significantly decreased in AML PBMCs and BMMCs compared to healthy donor PBMCs and BMMCs (Fig. 1a,b). We further confirmed elevated frequencies of IL-17A-producing cells in CD4+ cells from AML patients compared to healthy donors by qPCR, while IFN-γ-producing cells, although high, is not statistically significant by qPCR (Fig. 1c).
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.